Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis
Nonalcoholic Steatohepatitis (NASH) With Fibrosis Elafibranor NASH Nonalcoholic steatohepatitis Fatty liver disease Fibrosis Fatty Liver Non-alcoholic Fatty Liver Disease
You can join if…
Open to people ages 18–75
- Males or females aged from 18 to 75 years inclusive at first screening visit.
- Must provide signed written informed consent and agree to comply with the study protocol.
- BMI ≤45 kg/m².
- Females participating in the study must either not be of childbearing potential(hysterectomy, bilateral oophorectomy, medically documented ovarian failure, or >50 years of age with cessation of menses for at least 12 months due to ovarian failure)or using efficient double contraception: hormonal contraception (including patch,contraceptive ring, etc.), intra-uterine device, or other mechanical contraception method + condom or diaphragm or spermicide for the full duration of the study and for 1 month after the end of treatment.
- Histological confirmation of steatohepatitis on a diagnostic liver biopsy by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period) with at least 1 in each component of the NAS score(steatosis scored 0-3, ballooning degeneration scored 0-2, and lobular inflammation scored 0-3).
- NAS score ≥4.
- Fibrosis stage of 1 or greater and below 4, according to the NASH CRN fibrosis staging system.
- Stable dose of vitamin E, polyunsaturated fatty acids, or ursodeoxycholic acid from at least 6 months prior to diagnostic liver biopsy
- No change in antidiabetic therapy within 6 months prior to liver biopsy
You CAN'T join if...
- Known heart failure (Grade I to IV of New York Heart Association classification).
- History of efficient bariatric surgery within 5 years prior to screening.
- Uncontrolled hypertension
- Type 1 diabetes patients.
- Patients with decompensated diabetes (HbA1c>9%).
- Patients with a history of clinically significant acute cardiac event within 6 months prior to screening
- Weight loss of more than 5% within 6 months prior to randomization
- Compensated and decompensated cirrhosis
- Current or recent history (<5 years) of significant alcohol consumption
- . Pregnant or lactating females or females planning to become pregnant during the study period.
- . Other well documented causes of chronic liver disease according to standard diagnostic procedures
- . Patients with previous exposure to Elafibranor
- . Prohibited concomitant medication
- . Any medical conditions that may diminish life expectancy to less than 2 years including known cancers.
- . Evidence of any other unstable or untreated clinically significant immunological,endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease.
- . Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.
- University of California, San Francisco, Fresno Community Regional Medical Center accepting new patients
Fresno, California, 93721, United States
- University of California, San Francisco, Medical Center at Parnassus accepting new patients
San Francisco, California, 94143, United States
- Quest Clinical Research accepting new patients
San Francisco, California, 94115, United States
- Sutter West Bay Hospitals dba California Pacific Medical Center accepting new patients
San Francisco, California, 94115, United States
- Fresno Clinical Research Center accepting new patients
Fresno, California, 93720, United States
- Ventura Clinical Trials accepting new patients
Ventura, California, 93003, United States
- Cedars Sinai Medical Center accepting new patients
Los Angeles, California, 90048, United States
- Gastrointestinal Biosciences Clinical Trials LLC accepting new patients
Los Angeles, California, 90067, United States
- Veterans Affaires Greater Los Angeles Healthcare System, West LA VA Medical Center accepting new patients
Los Angeles, California, 90073, United States
- Ruane Clinical Research Group Inc. accepting new patients
Los Angeles, California, 90036, United States
- Keck Hospital of USC accepting new patients
Los Angeles, California, 90033, United States
- VA Long Beach Healthcare System accepting new patients
Long Beach, California, 90822, United States
- Rutgers, Robert Wood Johnson Medical School accepting new patients
New Brunswick, New Jersey, 89030, United States
- Alliance Clinical Research accepting new patients
Oceanside, California, 92056, United States
- accepting new patients
- Start Date
- Phase 3
- Study Type
- Last Updated
- March 5, 2018
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02704403.